skip to primary navigationskip to content
 

14.03.16 Launch event for the Milner Therapeutics Institute and Consortium

last modified Mar 15, 2016 03:23 PM
Pharmaceutical companies and academics gathered over dinner at Jesus College to launch the Milner Therapeutics Institute and Consortium
14.03.16 Launch event for the Milner Therapeutics Institute and Consortium

Prof. Tony Kouzarides

A dinner at Jesus College on 14th March was the setting for the official launch of the Milner Therapeutics Institute and Consortium, which will bring together pharmaceutical companies and researchers in Cambridge to study and develop better therapies for some of today’s most globally devastating diseases.

The Milner Institute and Therapeutics Consortium are led by Professor Tony Kouzarides, deputy director of the Wellcome Trust/ Cancer Research UK Gurdon Institute.

The Milner Therapeutics Institute, currently being constructed, will open in early 2018 and is situated within the new Capella Building on the Cambridge Biomedical Campus. The Institute will have space for senior and junior scientists to set up independent research groups and also communally accessible facilities, such as robotics and bioinformatics. The building of the Institute was made possible by a £5 million donation from entrepreneur Jonathan Milner, a former member of Professor Kouzarides' research group. In 1998 Jonathan Milner, Tony Kouzarides and David Cleevely founded biotechnology company Abcam, which has gone on to employ more than 800 people and supply products to 64 per cent of researchers globally.

The Milner Therapeutics Consortium is the outreach program of the Milner Institute, which is hosted at the Gurdon Institute until the new building is complete. It connects academic scientists and institutions in Cambridge with the pharmaceutical industry, to develop the therapeutic potential of their research. The Consortium, which has been operational since June 2015, is based on a partnership between three academic centres, the University of Cambridge, the Wellcome Trust Sanger Institute and the Babraham Institute, with four pharmaceutical companies: Astex, AstraZeneca, GlaxoSmithKline and Shionogi.

Professor Kouzarides said: “We hope many more pharmaceutical companies will join the Consortium and believe this form of partnership is a model for how academic institutions and industry can work together to deliver better medicines."

Studying development to understand disease

The Gurdon Institute is funded by Wellcome and Cancer Research UK to study the biology of development, and how normal growth and maintenance go wrong in cancer and other diseases.

combinedLogo x3 trans2018

 

Share this

Integrin signaling downregulates filopodia in muscle-tendon attachment

Defining Lineage Potential and Fate Behavior of Precursors during Pancreas Development

DDX3X RNA helicase affects breast cancer cell cycle progression by regulating expression of KLF4

Natural Genetic Variation in a Multigenerational Phenotype in C. elegans

On the origin of the human germline

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells 

Genome-Scale Oscillations in DNA Methylation during Exit from Pluripotency

Immune Cell Dynamics Unfolded by Single-Cell Technologies

Chromatin Accessibility Impacts Transcriptional Reprogramming in Oocytes

Integrin α2 marks a niche of trophoblast progenitor cells in first trimester human placenta

Inhibition of the acetyltransferase NAT10 normalizes progeric and aging cells by rebalancing the Transportin-1 nuclear import pathway

SLAM-ITseq: Sequencing cell type-specific transcriptomes without cell sorting

SRSF3 maintains transcriptome integrity in oocytes by regulation of alternative splicing and transposable elements

scmap: projection of single-cell RNA-seq data across data sets

Single-cell transcriptomics reveals a new dynamical function of transcription factors during embryonic hematopoiesis

Map of synthetic rescue interactions for the Fanconi anemia DNA repair pathway identifies USP48

The developmental origin of brain tumours: a cellular and molecular framework

 

 

Link to full list on PubMed